MX2013010507A - Metodo para reducir sintomas tipo gripe asociados con administracion intramuscular de interferon usando un regimen de dosificacion creciente de titulacion rapida. - Google Patents

Metodo para reducir sintomas tipo gripe asociados con administracion intramuscular de interferon usando un regimen de dosificacion creciente de titulacion rapida.

Info

Publication number
MX2013010507A
MX2013010507A MX2013010507A MX2013010507A MX2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A
Authority
MX
Mexico
Prior art keywords
intertruded
administration
symptoms associated
week
type
Prior art date
Application number
MX2013010507A
Other languages
English (en)
Other versions
MX359947B (es
Inventor
Aaron Deykin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MX2013010507A publication Critical patent/MX2013010507A/es
Publication of MX359947B publication Critical patent/MX359947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para tratar esclerosis múltiple (EM), y para reducir los síntomas tipo gripe asociados con la administración de un interferón a un paciente con EM. El método implica administrar intramuscularmente el interferón al paciente con EM de acuerdo a un régimen de dosificación creciente en las semanas 1 hasta 3, y una dosis terapéuticamente efectiva completa de interferón en la semana 4. En una modalidad de la invención, el régimen de dosificación creciente comprende administrar un cuarto de la dosis terapéuticamente efectiva en la semana 1, mitad de la dosis terapéuticamente efectiva en la semana 2, y tres cuartos de la dosis terapéuticamente efectiva en la semana 3. También se proporcionan envasados de titulación para permitir el cumplimiento de un régimen de cambiar la dosificación de un interferón durante un periodo de tiempo.
MX2013010507A 2011-03-15 2012-03-15 EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. MX359947B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
MX2013010507A true MX2013010507A (es) 2014-04-30
MX359947B MX359947B (es) 2018-10-17

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010507A MX359947B (es) 2011-03-15 2012-03-15 EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.

Country Status (25)

Country Link
US (6) US9198955B2 (es)
EP (1) EP2686002B1 (es)
JP (2) JP6279905B2 (es)
KR (1) KR102050339B1 (es)
CN (1) CN103702680A (es)
AU (1) AU2012229104B2 (es)
BR (1) BR112013023609A8 (es)
CA (1) CA2846786C (es)
CY (1) CY1120176T1 (es)
DK (1) DK2686002T3 (es)
EA (1) EA028448B1 (es)
ES (1) ES2666850T3 (es)
HR (1) HRP20180621T1 (es)
HU (1) HUE036931T2 (es)
IL (1) IL228425A (es)
LT (1) LT2686002T (es)
MX (1) MX359947B (es)
PL (1) PL2686002T3 (es)
PT (1) PT2686002T (es)
RS (1) RS57175B1 (es)
SG (1) SG193446A1 (es)
SI (1) SI2686002T1 (es)
SM (1) SMT201800221T1 (es)
WO (1) WO2012125809A1 (es)
ZA (1) ZA201306933B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800221T1 (it) * 2011-03-15 2018-07-17 Biogen Ma Inc Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida
WO2015105201A1 (en) * 2014-01-09 2015-07-16 Kyushu University, National University Corporation Method of producing microglial cells
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
KR101042660B1 (ko) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
EP1605992B1 (en) * 2003-01-30 2018-11-21 Becton, Dickinson and Company Holder with safety shield for a drug delivery device
EP1750751B1 (en) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
DK2486916T3 (en) 2006-12-18 2015-06-15 Ajinomoto Althea Inc Formulations of Human Growth Hormone
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
CN102695499A (zh) * 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
SMT201800221T1 (it) * 2011-03-15 2018-07-17 Biogen Ma Inc Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida

Also Published As

Publication number Publication date
EA028448B1 (ru) 2017-11-30
EA201301024A1 (ru) 2014-03-31
US20250276042A1 (en) 2025-09-04
SMT201800221T1 (it) 2018-07-17
US9198955B2 (en) 2015-12-01
ZA201306933B (en) 2016-07-27
JP6279905B2 (ja) 2018-02-14
JP2018030847A (ja) 2018-03-01
HRP20180621T1 (hr) 2018-07-27
BR112013023609A2 (pt) 2016-12-06
SG193446A1 (en) 2013-10-30
PT2686002T (pt) 2018-04-23
US20200046804A1 (en) 2020-02-13
CA2846786C (en) 2022-05-17
MX359947B (es) 2018-10-17
US20160101157A1 (en) 2016-04-14
US10500254B2 (en) 2019-12-10
KR20140038383A (ko) 2014-03-28
PL2686002T3 (pl) 2018-10-31
LT2686002T (lt) 2018-05-10
EP2686002A1 (en) 2014-01-22
EP2686002B1 (en) 2018-01-24
WO2012125809A1 (en) 2012-09-20
JP6522069B2 (ja) 2019-05-29
US20170360890A1 (en) 2017-12-21
US20120237479A1 (en) 2012-09-20
SI2686002T1 (en) 2018-06-29
CN103702680A (zh) 2014-04-02
AU2012229104B2 (en) 2017-03-16
NZ616536A (en) 2015-10-30
ES2666850T3 (es) 2018-05-08
IL228425A (en) 2017-08-31
NZ712273A (en) 2016-09-30
AU2012229104A1 (en) 2013-10-03
US20220280610A1 (en) 2022-09-08
CY1120176T1 (el) 2018-12-12
RS57175B1 (sr) 2018-07-31
HUE036931T2 (hu) 2018-08-28
KR102050339B1 (ko) 2019-11-29
DK2686002T3 (en) 2018-04-30
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
JP2014508174A (ja) 2014-04-03
IL228425A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
CR20140086A (es) Tratamientos de combinación para hepatitis c
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
BR112013025969A2 (pt) forma de dose unitária para administração oral
BR112015026325A2 (pt) dosagem oral de compostos glp-1
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2013008012A (es) Tratamiento para la lipodistrofia.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
ECSP13012791A (es) Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina
MX2013010507A (es) Metodo para reducir sintomas tipo gripe asociados con administracion intramuscular de interferon usando un regimen de dosificacion creciente de titulacion rapida.
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
DOP2013000206A (es) Inhibidores de la peptido desformilasa
MX390369B (es) Inhibidores tripeptidicos de la epoxicetona proteasa
BR112014015314A2 (pt) composição farmacêutica não entérica compreendendo crofelemer
ECSP13012369A (es) Agentes terapéuticos 976
PL3897598T3 (pl) Niewodne roztwory kurkuminoidów możliwe do podawania w wysokich dawkach terapeutycznych
CL2013003671A1 (es) Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor.
RU2010130512A (ru) Способ лечения деструктивного туберкулеза легких
UA99811U (ru) Способ лечения патогенно индуцированного апоптоза гепатоцитов при алкогольных поражениях печени
RU2012156088A (ru) Способ лечения вульгарной пузырчатки

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: PFIZER, INC.

GB Transfer or rights

Owner name: BIOGEN MA INC.

FG Grant or registration